Work

Phase 2 Clinical Evaluation of Preclinically Defined Biomarkers for Vascular Endothelial Growth Factor (Vegf) Tyrosine Kinase Inhibitor (Tki) Tivozanib in Renal Cell Carcinoma (Rcc)

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu326.66

Authors: T. Hutson, W.K. Rathmell, B. Feng, M.O. Robinson, J. Gyuris, J. Lin, T. Choueiri

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, AVEO Oncology (United States), Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2311213076

FWCI:

Cites:

Cited by: 1

Related to: 10